SCHEMBL2808135

SCHEMBL2808135

Cc1ccc2oc(=O)c(C(=O)O)cc2c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 9/20 1.00
CA12 O43570 4/20 1.00
CA1 P00915 4/20 1.00
CA6 P23280 4/20 1.00
CA7 P43166 4/20 1.00
CA9 Q16790 4/20 1.00
CA14 Q9ULX7 4/20 1.00
CA5B Q9Y2D0 4/20 1.00
CA2 P00918 3/20 1.00
CA5A P35218 3/20 1.00
CA4 P22748 3/20 1.00
MAOA P21397 2/20 0.69
GPR35 Q9HC97 4/20 0.67
KDM4E B2RXH2 2/20 0.67
ALDH1A1 P00352 2/20 0.67
GRIN1 Q05586 1/20 0.67
GRIN2A Q12879 1/20 0.67
GRIN2B Q13224 1/20 0.67
GRIN2C Q14957 1/20 0.67
CYP1A2 P05177 1/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1368129 0.88 MAOB (0.79) MAOBCA12CA1CA6CA7
SCHEMBL14642321 0.87 MAOB (0.77) MAOBCA12CA1CA6CA7
SCHEMBL10305750 0.87 CA12 (0.77) MAOBCA12CA1CA6CA7
SCHEMBL9989055 0.85 MAOB (0.74) MAOBCA12CA1CA6CA7
SCHEMBL18589240 0.83 MAOB (0.70) MAOBCA12CA1CA6CA7
SCHEMBL28703856 0.81 MAOB (0.68) MAOBCA12CA1CA6CA7
SCHEMBL31457861 0.81 MAOB (0.68) MAOBCA12CA1CA6CA7
SCHEMBL29785071 0.81 MAOA (1.00) MAOBCA12CA1CA6CA7
SCHEMBL11266285 0.81 MAOA (0.71) MAOBCA12CA1CA6CA7
SCHEMBL979779 0.81 MAOA (1.00) MAOBCA12CA1CA6CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8968711-B2 Cosmetic or dermatological composition comprising a polymer bearing junction groups, and cosmetic treatment process L'OREAL (FR) 2015-03-03 US claimed
US-20100272660-A1 COSMETIC OR PHARMACEUTICAL COMPOSITION COMPRISING A POLYCONDENSATE, THE SAID POLYCONDENSATE AND METHOD OF COSMETIC TREATMENT L'OREAL (FR) 2010-10-28 US claimed
US-20100239509-A1 COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING A POLYMER BEARING JUNCTION GROUPS, AND COSMETIC TREATMENT PROCESS L'OREAL (FR) 2010-09-23 US claimed
CN-119192113-A Pleuromutilin derivative and preparation method and application thereof 西华大学 2024-12-27 CN disclosed
CN-116693487-A Coumarin-based thioester photoinitiator suitable for photopolymerization and preparation method thereof 北京化工大学 2023-09-05 CN disclosed
WO-2023094734-A1 LIGANDS SPECIFICALLY TARGETING VESICULAR GLUTAMATE TRANSPORTERS FOR SUPER-RESOLUTION IMAGING Sorbonne Université (FR) 2023-06-01 WO disclosed
CN-111455005-B Method for synthesizing coumarin-3-carboxylic acid-6' -O-D-sucrose ester derivative on line enzymatically based on flow chemistry 浙江农林大学 2023-05-05 CN disclosed
CN-110804045-B Coumarin hybrid pyridone amide derivative with potential anti-AD activity and preparation method and application thereof 浙江工业大学 2021-07-27 CN disclosed
CN-107445933-B 3-coumarin formic acid compound and application thereof in preparation of phytopathogen antibacterial agent 西北农林科技大学 2021-03-23 CN disclosed
CN-111455005-A Method for synthesizing coumarin-3-carboxylic acid-6' -O-D-sucrose ester derivative through on-line enzymatic synthesis based on flow chemistry 浙江农林大学 2020-07-28 CN disclosed
CN-110804045-A Coumarin hybrid pyridone amide derivative with potential anti-AD activity and preparation method and application thereof 浙江工业大学 2020-02-18 CN disclosed
US-20100272660-A1 COSMETIC OR PHARMACEUTICAL COMPOSITION COMPRISING A POLYCONDENSATE, THE SAID POLYCONDENSATE AND METHOD OF COSMETIC TREATMENT L'OREAL (FR) 2010-10-28 US disclosed
US-20100239509-A1 COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING A POLYMER BEARING JUNCTION GROUPS, AND COSMETIC TREATMENT PROCESS L'OREAL (FR) 2010-09-23 US disclosed
US-20090028807-A1 COMPOSITION COMPRISING A POLYCONDENSATE, METHOD OF TREATMENT, POLYCONDENSATE, AND METHOD OF PREPARATION L'OREAL (FR) 2009-01-29 US disclosed
US-6355658-B1 COUMARIN ESTERS WITH ETHER GROUPS CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2002-03-12 US disclosed
EP-0988298-A1 COUMARIN DERIVATIVES, METHODS OF PREPARATION AND APPLICATION AS MEDICINES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2000-03-29 EP disclosed
WO-1998055472-A1 COUMARIN DERIVATIVES, METHODS OF PREPARATION AND APPLICATION AS MEDICINES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 1998-12-10 WO disclosed
US-4343938-A 7-[Dα-(Coumarin-3-carboxamido)arylacetamido]-cephalosporanic acids or salts AMERICAN CYANAMID COMPANY (US) 1982-08-10 US disclosed
US-4317774-A 6-[D-α-(Coumarin-3-carboxamido)arylacetamido]-penicillanic acids or salts AMERICAN CYANAMID COMPANY (US) 1982-03-02 US disclosed
US-4159268-A ANTIBIOTICS, MICROBIOCIDES AMERICAN CYANAMID COMPANY (US) 1979-06-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100239509-A1 COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING A POLYMER BEARING JUNCTION GROUPS, AND COSMETIC TREATMENT PROCESS CUTA, SUCLG1, KRT18 MAOB 1498/4885CA12 15/4885CA1 185/4885
US-20090028807-A1 COMPOSITION COMPRISING A POLYCONDENSATE, METHOD OF TREATMENT, POLYCONDENSATE, AND METHOD OF PREPARATION CUTA, SYMPK, TPRKB MAOB 3522/4885CA12 3507/4885CA1 4550/4885
US-20100272660-A1 COSMETIC OR PHARMACEUTICAL COMPOSITION COMPRISING A POLYCONDENSATE, THE SAID POLYCONDENSATE AND METHOD OF COSMETIC TREATMENT ACMSD, CUTA, PCCA MAOB 3151/4885CA12 403/4885CA1 1334/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.